We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

VALMT:OMXHEXValmet Corp Analysis

Data as of 2026-06-22 - not real-time

€22.02

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Valmet currently trades at €22.02, well below its DCF‑derived fair value of €26.53, implying ~28.7% upside. The stock also trades at a trailing P/E of 15.96 versus an industry average of 31.42, reinforcing the undervaluation thesis. Revenue growth of 5.1% and a 6.06% dividend yield add to the appeal, though the payout ratio sits near 98% of earnings.
Technicals show a bearish bias – price is under the 20‑day (22.49) and 50‑day (23.21) SMAs and the 200‑day SMA (26.81), with the RSI at 42 and MACD histogram just turning positive. Support sits at €21.36 and resistance at €23.66, suggesting limited near‑term upside unless momentum shifts. Volume is increasing, but current daily volume (≈40k) is far below the 10‑day average (270k), indicating modest liquidity.
The company’s low beta (~0.39) and diversified geographic footprint mitigate market risk, while a 23.9% 30‑day volatility and a max drawdown of ~33% flag moderate price swings. Strong cash generation (operating cash flow €399 m) supports the high dividend, but the near‑full earnings payout raises sustainability concerns. Overall, Valmet appears priced for a turnaround, with valuation and fundamentals outweighing short‑term technical weakness.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish technical positioning (price below SMAs, RSI 42)
  • Undervalued valuation with ~28% upside
  • High dividend yield but near‑full earnings payout

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • DCF upside and low P/E vs peers
  • Improving cash flow and low beta
  • Growing demand for sustainable pulp and bio‑materials

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Long‑term industry tailwinds in circular economy
  • Strong market position and diversified geography
  • Attractive dividend yield if payout can be moderated

Key Metrics & Analysis

Financial Health

Revenue Growth5.10%
Profit Margin4.81%
P/E Ratio16.0
ROE10.46%
ROA4.86%
Debt/Equity61.23
P/B Ratio1.7
Op. Cash Flow€399.0M
Free Cash Flow€352.1M
Industry P/E31.4

Technical Analysis

TrendBearish
RSI42.0
Support€21.36
Resistance€23.66
MA 20€22.49
MA 50€23.21
MA 200€26.81
MACDBullish
VolumeIncreasing
Fear & Greed Index90.3

Valuation

Fair Value€26.53
Target Price€28.33
Upside/Downside28.67%
GradeUndervalued
TypeBlend
Dividend Yield6.06%

Risk Assessment

Beta0.39
Volatility23.86%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.